X

DBL BLEOMYCIN SULFATE FOR INJECTION 15000 IU/VIAL

Product Information

Registration Status: Active

SIN08426P

DBL BLEOMYCIN SULFATE FOR INJECTION 15000 IU/VIAL is approved to be sold in Singapore with effective from 1995-10-26. It is marketed by HOSPIRA SINGAPORE PTE LTD, with the registration number of SIN08426P.

This product contains Bleomycin 15000 iu/vial in the form of INJECTION, POWDER, FOR SOLUTION. It is approved for INTRAVENOUS, SUBCUTANEOUS, INTRAMUSCULAR use.

This product is manufactured by Hospira Australia Pty Ltd in AUSTRALIA, andZydus Hospira Oncology Private Limited (ZHOPL) in INDIA.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Product Reference
Loading...


Description

A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.

Indication

For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.

Mechanism of Action

Although the exact mechanism of action of bleomycin is unknown, available evidence would seem to indicate that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis. DNA cleavage by bleomycin depends on oxygen and metal ions, at least in vitro. It is believed that bleomycin chelates metal ions (primarily iron) producing a pseudoenzyme that reacts with oxygen to produce superoxide and hydroxide free radicals that cleave DNA.

Pharmacokinetics

Absorption
Systemic absorption is approximately 45%.
Distribution
Metabolism
Hepatic
Elimination

Toxicity

Excessive exposure may cause fever, chills, nausea, vomiting, mental, confusion, and wheezing. Bleomycin may cause irritation to eyes, skin and respiratory tract. It may also cause a darkening or thickening of the skin. It may cause an allergic reaction.

Active Ingredient/Synonyms

Bleocin | Bleomicin | Bleomicina | Bleomycin A2 | Bleomycine | Bleomycinum | BLM | Bleomycin |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank

Pharmfair.com uses cookies to improve your browsing experience. We'll assume you're ok with this, but you can opt-out if you wish. Peace!